Papers
2
Total Citations
69
H-Index
2
About
K. Thomas is a pioneering radiation oncologist whose research focuses on stereotactic body radiation therapy (SBRT) for early-stage breast cancer, particularly through partial-breast irradiation (PBI). Their major contribution lies in demonstrating the safety and feasibility of ultra-hypofractionated 5-fraction SBRT regimens, challenging conventional longer-course treatments. Thomas’s landmark 2017 Phase 1 dose-escalation trial (66 citations) established key toxicity and efficacy benchmarks, showing that high-dose-per-fraction SBRT can be delivered with acceptable side effects, paving the way for shorter, more convenient breast cancer treatments. This work has influenced clinical trial design and practice patterns in radiation oncology. Their earlier 2016 Phase 1 trial (3 citations) laid foundational dose-escalation data. Thomas’s research directly addresses the critical need for de-escalation of breast radiotherapy, improving patient quality of life while maintaining oncologic outcomes. Their contributions are particularly notable for advancing SBRT as a viable alternative to whole-breast irradiation, with implications for reducing treatment burden and healthcare costs. Thomas’s work continues to shape the evolving landscape of breast cancer radiation therapy.
Research Focus
Key Achievements
Top Papers
- 1
- 2